Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald A Berry

Showing results (71-80 of 197) with videos related to

Pageof 20
Sort By:
Alzheimer'S Research & Therapy|December 9, 2022
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's diseaseShobha Dhadda, Michio Kanekiyo, David Li, et al.
Cancer Causes & Control : CCC|April 9, 2013
Meta-analyses of colorectal cancer risk factorsConstance M Johnson, Caimiao Wei, Joe E Ensor, et al.
Genetics|September 25, 2003
Assessing probability of ancestry using simple sequence repeat profiles: applications to maize inbred lines and soybean varietiesDonald A Berry, Jon D Seltzer, Chongqing Xie, et al.
Neuro-Oncology|July 17, 2013
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2Brian M Alexander, Patrick Y Wen, Lorenzo Trippa, et al.
JAMA Network Open|April 11, 2023
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical TrialDonald A Berry, Shobha Dhadda, Michio Kanekiyo, et al.
Clinical Trials (London, England)|March 27, 2010
A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drugScott M Berry, Walter Spinelli, Gary S Littman, et al.
Journal of the American College of Surgeons|January 17, 2017
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)David W Ollila, Constance T Cirrincione, Donald A Berry, et al.
Clinical Research and Regulatory Affairs|December 2, 2015
Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative StudyTimothy C Guetterman, Michael D Fetters, Laurie J Legocki, et al.
The New England Journal of Medicine|April 20, 2007
The decrease in breast-cancer incidence in 2003 in the United StatesPeter M Ravdin, Kathleen A Cronin, Nadia Howlader, et al.
Molecular and Cellular Biology|September 19, 2006
MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradationJer-Yen Yang, Cong S Zong, Weiya Xia, et al.
Pageof 20

Showing results (71-80 of 197) with videos related to

Sort By:
Pageof 20
Alzheimer'S Research & Therapy|December 9, 2022
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's diseaseShobha Dhadda, Michio Kanekiyo, David Li, et al.
Cancer Causes & Control : CCC|April 9, 2013
Meta-analyses of colorectal cancer risk factorsConstance M Johnson, Caimiao Wei, Joe E Ensor, et al.
Genetics|September 25, 2003
Assessing probability of ancestry using simple sequence repeat profiles: applications to maize inbred lines and soybean varietiesDonald A Berry, Jon D Seltzer, Chongqing Xie, et al.
Neuro-Oncology|July 17, 2013
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2Brian M Alexander, Patrick Y Wen, Lorenzo Trippa, et al.
JAMA Network Open|April 11, 2023
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical TrialDonald A Berry, Shobha Dhadda, Michio Kanekiyo, et al.
Clinical Trials (London, England)|March 27, 2010
A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drugScott M Berry, Walter Spinelli, Gary S Littman, et al.
Journal of the American College of Surgeons|January 17, 2017
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)David W Ollila, Constance T Cirrincione, Donald A Berry, et al.
Clinical Research and Regulatory Affairs|December 2, 2015
Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative StudyTimothy C Guetterman, Michael D Fetters, Laurie J Legocki, et al.
The New England Journal of Medicine|April 20, 2007
The decrease in breast-cancer incidence in 2003 in the United StatesPeter M Ravdin, Kathleen A Cronin, Nadia Howlader, et al.
Molecular and Cellular Biology|September 19, 2006
MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradationJer-Yen Yang, Cong S Zong, Weiya Xia, et al.
Pageof 20